

LABORATORY CORP OF AMERICA HOLDINGS
Form 8-K
February 22, 2010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 22, 2010
(Date of earliest event reported)

**LABORATORY CORPORATION OF
AMERICA HOLDINGS**

(Exact Name of Registrant as Specified in its Charter)

DELAWARE

1-11353

13-3757370

(State or other jurisdiction
of Incorporation)

(Commission
File Number)

(I.R.S.
Employer
Identification
No.)

**358 SOUTH MAIN STREET,
BURLINGTON, NORTH CAROLINA**

27215

336-229-1127

(Address of principal executive offices)

(Zip
Code)

(Registrant's telephone number including area
code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure

Summary information of the Company in connection with non-deal related meetings at Barclays Capital in New York, NY on February 23, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Laboratory Corporation of America Holdings
(Registrant)

Date: February 22, 2010

By: /s/F. Samuel Eberts III
F. Samuel Eberts III, Chief Legal Officer
and Secretary

New York, NY

February 23, 2010

Barclays Capital

NDR

2

This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.

Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2008, and subsequent SEC filings.

Forward Looking Statement

Introduction

3

Leading National

Lab Provider

Fastest growing national lab

\$55 billion market

Clinical, Anatomic and Genomic Testing

Serving clients in all 50 states and Canada

Foremost clinical trials testing business

Introduction

4

Valuable Service

Small component of total cost

influences large percentage

of clinical decisions

Screening, early detection,

and monitoring reduce

downstream costs

Companion diagnostics

improve drug efficacy and

reduce adverse drug effects

Attractive Market

5

Attractive Market

6

Growth Drivers

Aging population

Industry consolidation

Advances in genomics

Pharmacogenomics /

companion diagnostics

Cost pressures

Source: CDC National Ambulatory Medical Care Survey and Company Estimates

Attractive Market

7

Opportunity to

Take Share

Approximately 5,000

independent labs

High cost competitors

Source: Washington G-2 Reports and company estimates

\$55 Billion US Lab Market

55%

14%

9%

4%

19%

Hospital Affiliated

Quest

LabCorp

Physician Office

Other Independent

Attractive Market

Diversified Payor Mix

No customer > 9% of revenue

Limited government exposure

8

Attractive Market

Diversified Test Mix

Esoteric 36% of revenue

Goal of 40% in 3 - 5 years

Higher priced business

9

Competitive Position

Scale and Scope

National infrastructure

Broad test offering

Managed care contracts

Economies of scale

10

Primary LabCorp Testing Locations*

Esoteric Lab Locations

(CET, CMBP, Dianon, Esoterix, Monogram Biosciences, NGI, OTS, US Labs, Viromed)

Patient Service Centers*

Competitive Position

11

Managed Care Relationships

Exclusive national laboratory for UnitedHealthcare

Sole national strategic partner for WellPoint

Significant national plans recently renewed or

extended on a multi-year basis, including

WellPoint, Cigna and Humana

Contracted with numerous local and

regional anchor plans

Scientific

Leadership

Introduction of new tests

Acquisitions and licensing

Collaborations with leading

companies and academic

institutions

Competitive Position

12

Competitive Position

13

Standardized and

Efficient Processes

Standardized lab and billing

IT systems

Automation of pre-analytics

Capacity rationalization

Logistics optimization

2010 Priorities

14

Our Focus

Profitable revenue growth

IT and client connectivity

Continue scientific

leadership

Maintain price

Control costs

2010 Priorities

15

Profitable Revenue Growth

Target specialty physicians with
breadth of menu and services

Educate payers and physicians on
value of LabCorp testing

Leverage assets from Monogram
acquisition

Continue to improve patient experience

2010 Priorities

16

**IT and Client
Connectivity**

Enhance online services and
analytic tools

LabCorp Inside the Box for
superior connectivity

Improve Patient Experience
through:

Automated PSC workflow

Patient access via PHRs,
online appointments

Enterprise services
including VoIP

Continue open platform strategy
to maximize options for users

Continue Scientific

Leadership

Increase esoteric testing

Grow and enhance offerings in
personalized medicine:

Expand outcome improvement
programs

Develop and commercialize
companion diagnostics

2010 Priorities

17

Increase

Esoteric Testing

Introduction of new tests

Acquisitions and licensing

Collaborations with academic
institutions

Continue Scientific Leadership

18

New Tests Include:

Collaborations Include:

BRAF Gene Mutation Detection

EGRF Mutation Analysis for Nonsmall-Cell Lung Cancer

Warfarin (P450 2C9 and VKORC1)

Clopidogrel CYP2C19 Genotyping

Duke University

National Jewish Health

Integrase HIV Genotyping (GenoSure) and HIV Phenotyping (PhenoSense)

HERmark for Breast Cancer

????

Yale University

Enhanced Trofile

H1N1 Flu Testing

Expand Outcomes

Improvement

Litholink kidney stone

CKD

Continual development of

valuable programs

Continue Scientific Leadership

19

Continue Scientific Leadership

20

Develop and Commercialize

Companion Diagnostics

Invest in clinical trials

Relationships with biotech and

pharma companies

Promote key tests

K-RAS

HLA-B* 5701

BRAF Gene Mutation Detection

EGRF Mutation Analysis

CYP 450 2C19

Monogram Biosciences

Trofile

PhenoSense, PhenoSense GT

HERmark

K-RAS testing should be routinely conducted in all colorectal cancer patients immediately after diagnosis to ensure the best treatment strategies for the individual Patient

Dr. Eric Van Cutsem, presenter at the June 2008 American

Society of Clinical Oncology meeting

FDA recommends genetic screening prior to treatment with Abacavir

ROCKVILLE, Md -- July 24, 2008 -- The US Food and Drug Administration (FDA) has issued an alert regarding serious, and sometimes fatal, hypersensitivity reactions (HSRs) caused by abacavir (Ziagen) therapy in patients with a particular human leukocyte antigen (HLA) allele, HLA-B* 5701.

Genetic tests for HLA-B*5701 are already available, and all patients should be screened for the HLA-B*5701 allele before starting or restarting treatment with abacavir or abacavir-containing medications.

FDA has approved the expanded use of Selzentry to include adult patients with CCR5-tropic HIV-1 virus who are starting treatment for the first time.

- ViiV Healthcare Press Release, November 20th, 2009

2010 Priorities

Maintain Price

Managed care stability; offsets

1.9% Medicare rate decrease

Focus on high-value tests

Promote outcome improvement

21

Control Costs

Continue focus on collections

and bad debt reduction

Optimize supply chain

Use efficiency gains to

improve patient experience

2010 Priorities

22

\$3,085

\$3,328

\$3,591

\$4,068

\$4,513

\$4,695

\$2.45

\$2.80

\$3.30

\$4.18

\$4.60

\$4.89

2004

2005

2006

2007

2008

2009

Revenue (\$mil)

EPS

Excellent Performance

23

Revenue and

EPS Growth

9% Revenue CAGR

15% EPS CAGR

(1) Excluding the \$0.09 per diluted share impact in 2005 of restructuring and other special charges, and a non-recurring investment loss; excluding the \$0.06 per diluted share impact in 2006 of restructuring and other special charges; excluding the \$0.25 per diluted share impact in 2007 of restructuring and other special charges; excluding the

(2) EPS, as presented, represents adjusted, non-GAAP financial measures. Diluted EPS, as reported in the Company's Annual Report were: \$2.45 in 2004; \$2.71 in 2005; \$3.24 in 2006; \$3.93 in 2007; \$4.16 in 2008; and \$4.98 in 2009.

\$0.44 per diluted share impact in 2008 of restructuring and other special charges; excluding the (\$0.09) per diluted share impact in 2009 of restructuring and other special charges.

Revenue and EPS Growth: 2004 - 2009^{(1) (2)}

Excellent Performance

24

Leading Returns

Leading returns

Leading EBIT margin

18.2%

20.5%

21.8%

27.6%

27.5%

25.8%

0.0%

5.0%

10.0%

15.0%

20.0%

25.0%

30.0%

2004

2005

2006

2007

2008

2009

LabCorp ROE 2004-2009

Excellent Performance

25

Cash Flow

11% FCF CAGR

\$2.0 B+ share repurchase

over last three years

Note: \$ in Millions

\$538

\$574

\$632

\$710

\$781

\$862

\$443

\$481

\$516

\$567

\$624

\$748

\$

-

\$200

\$400

\$600

\$800

\$1,000

2004

2005

2006

2007

2008

2009

Operating Cash Flow

Free Cash Flow

Fourth Quarter and Full Year 2009 Results

26

2009

2008

+ / (-)

2009

2008

+ / (-)

Adjusted Revenue

1,165.1

\$

1,126.6

\$

3.4%

4,694.7

\$

4,512.7

\$

4.0%

Adjusted Operating Income

221.9

\$

219.8

\$

1.0%

954.9

\$

937.0

\$

1.9%

Adjusted Operating Income Margin

19.0%

19.5%

(50)

bp

20.3%

20.8%

(50)

bp

Adjusted EPS

1.16

\$

1.10

\$

5.5%

4.89

\$

4.60

\$

6.3%

Operating Cash Flow

224.7

\$

215.3

\$

4.4%

862.4

\$

780.9

\$

10.4%

Less: Capital Expenditures

(37.6)

\$

(36.3)

\$

3.6%

(114.7)

\$

(156.7)

\$

-26.8%

Free Cash Flow

187.1

\$

179.0

\$

4.5%

747.7

\$

624.2

\$

19.8%

Twelve Months Ended Dec 31,

Three Months Ended Dec 31,

Supplemental Financial Information

27

Q1 09

Q2 09

Q3 09

Q4 09

2009

Bad debt as a percentage of sales

5.3%

5.3%

5.3%

5.3%

5.3%

Days sales outstanding

52

50

48

44

44

A/R coverage (Allowance for Doubtful Accts. / A/R)

19.5%

20.6%

21.9%

23.2%

23.2%

Laboratory Corporation of America

Other Financial Information

Full Year 2009

(\$ in million's)

Key Points

Critical position in health care delivery system

Attractive market

Strong competitive position - well positioned to gain share

Leadership in personalized medicine

Excellent cash flow

Strong balance sheet

Conclusion

28
